Suzhou Basecare Medical Corporation Limited Stock price

Equities

2170

CNE100004BC1

Healthcare Facilities & Services

Delayed Hong Kong S.E. 04:08:03 2024-03-28 am EDT 5-day change 1st Jan Change
2.01 HKD -0.50% Intraday chart for Suzhou Basecare Medical Corporation Limited 0.00% -14.47%

Financials

Sales 2023 208M 28.78M 225M Sales 2024 * 459M 63.45M 497M Capitalization 494M 68.3M 534M
Net income 2023 -192M -26.57M -208M Net income 2024 * -78M -10.79M -84.47M EV / Sales 2023 2.73 x
Net cash position 2023 * - 0 0 Net cash position 2024 * - 0 0 EV / Sales 2024 * 1.08 x
P/E ratio 2023
-3.05 x
P/E ratio 2024 *
-6.31 x
Employees 488
Yield 2023 *
-
Yield 2024 *
-
Free-Float 26.54%
More Fundamentals * Assessed data
Dynamic Chart
Suzhou Basecare Medical Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Suzhou Basecare Medical Corporation Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Suzhou Basecare Medical Corporation Limited Announces Board Appointments CI
Suzhou Basecare Medical's Expects Gross Profit to Jump Up To 20.5% in First Half MT
Suzhou Basecare Medical Corporation Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2023 CI
Suzhou Basecare Medical Corporation Limited Announces Executive Changes CI
Suzhou Basecare Completes $40 Million Acquisition of Singaporean Fertility Products Provider MT
Suzhou Basecare Medical Corporation Limited completed the acquisition of BMX Holdco Pte. Ltd. from individual investors and funds. CI
Suzhou Basecare Medical Corporation Limited Announces Resignation of Chau Kwok Keung Independent Non-Executive Director, Effect from June 14, 2023 CI
Suzhou Basecare Medical to Buy Entire Stake in Singapore-Based Fertility Products Provider MT
Suzhou Basecare Medical Corporation Limited entered into an agreement to acquire BMX Holdco Pte. Ltd. from individual investors and funds for approximately CNY 280 million. CI
Suzhou Basecare Medical Trims Loss in 2022 as Revenue Jumps 31% MT
Suzhou Basecare Medical Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Over a dozen Chinese-based firms say they have minimal exposure to SVB RE
Suzhou Basecare Medical Eyes Shanghai IPO MT
More news
1 day-0.50%
Current month-1.95%
1 month+1.01%
3 months-17.96%
6 months-28.21%
Current year-14.47%
More quotes
1 week
1.98
Extreme 1.98
2.15
1 month
1.84
Extreme 1.84
2.34
Current year
1.84
Extreme 1.84
2.40
1 year
1.84
Extreme 1.84
4.94
3 years
1.84
Extreme 1.84
28.90
5 years
1.84
Extreme 1.84
34.85
10 years
1.84
Extreme 1.84
34.85
More quotes
Managers TitleAgeSince
Chief Executive Officer 44 10-12-13
Director of Finance/CFO 39 22-11-27
Chief Operating Officer 36 14-11-16
Members of the board TitleAgeSince
Director/Board Member 72 21-01-15
Chief Executive Officer 44 10-12-13
Chief Operating Officer 36 14-11-16
More insiders
Date Price Change Volume
24-03-28 2.01 -0.50% 20,500
24-03-27 2.02 +1.00% 110,000
24-03-26 2 +1.01% 8,500
24-03-25 1.98 0.00% 241,000
24-03-22 1.98 -1.49% 2,500

Delayed Quote Hong Kong S.E., March 28, 2024 at 04:08 am EDT

More quotes
Suzhou Basecare Medical Co Ltd, formerly Jiangsu Double Helix Biology Science and Technology Co Ltd, is a China-based investment holding company mainly engaged in the provision of assisted reproductive genetic testing solutions. The Company provides genetic testing solutions and sells genetic testing equipment and instruments. The genetic testing solutions include sales of testing kits and provision of testing services. The Company's main products include PGT-A kits. The Company mainly conducts business within the domestic market.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.856 CNY
Average target price
11.18 CNY
Spread / Average Target
+502.49%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Suzhou Basecare Medical Corporation Limited - Hong Kong S.E.